Multi-target RNA interference: A disruptive next-generation strategy for precision treatment of rheumatoid arthritis

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune joint inflammation with limited efficacy and side effects from current treatments like DMARDs and biologics.
• RNA interference (RNAi) using small interfering RNA (siRNA) presents a novel therapeutic strategy for RA by targeting specific disease-driving molecules.
• Existing therapies often fail to address the complex, multi-factorial nature of RA pathogenesis.

Purpose of the Study:

• To systematically review the therapeutic potential of siRNA in treating rheumatoid arthritis (RA).
• To analyze the mechanisms by which siRNA targets key inflammatory pathways and cellular processes in RA.
• To evaluate the efficacy and challenges of siRNA-based therapies in preclinical RA models.

Main Methods:

• Systematic review of 140 studies on therapeutic siRNA for RA.
• Analysis of siRNA's impact on macrophage and fibroblast-like synoviocyte (FLS) activation.
• Evaluation of siRNA's effects on inflammatory pathways (TNF-α, IL-1, IL-6, NF-κB, inflammasomes), immune cell differentiation (Th17, Treg), and FLS aggressiveness (CCN1, KHDRBS1, E2F2).
• Review of experimental data from rodent models using nanoparticle-delivered siRNA.

Main Results:

• siRNA effectively inhibits key RA drivers like TNF-α, IL-1, IL-6, and NF-κB.
• siRNA suppresses macrophage and FLS activation by targeting TNF, RELA, and MAPK/JAK pathways.
• siRNA reduces inflammation by targeting NLRP3 inflammasome and modulates immune balance by downregulating Th17 and upregulating Treg functions.
• siRNA inhibits FLS aggressiveness by targeting CCN1, KHDRBS1, and E2F2.
• Nanoparticle-delivered siRNA in rodent models significantly reduced paw inflammation and joint destruction.

Conclusions:

• Multi-target siRNA therapy provides a precise mechanism to inhibit RA's intracellular inflammatory cascade and joint damage progression.
• siRNA demonstrates potential to overcome limitations of conventional RA treatments by addressing multiple pathological pathways simultaneously.
• Advancements in siRNA stability, delivery, and nanoparticle technology are crucial for clinical translation, offering a promising future for RA management.